Neurology Department, Brugmann University Hospital, Brussels, Belgium.
J Clin Psychopharmacol. 2012 Jun;32(3):412-5. doi: 10.1097/JCP.0b013e3182524511.
This retrospective study aimed to evaluate the incidence of transdermal rivastigmine treatment withdrawal secondary to adverse skin reactions among the patients from our Memory Clinic. In addition, we tested whether climatic conditions might have an influence on skin irritations leading to eventual treatment disruption.
We performed a retrospective review of patients from the Brugmann University Hospital Memory Clinic having started transdermal rivastigmine between June 2008 and December 2010. Local meteorological data were provided by the Royal Meteorological Institute of Belgium.
A total of 26.9% of the patients experienced adverse skin reactions at the rivastigmine application site, leading to treatment discontinuation in 19.2% of the cases. Rivastigmine cutaneous tolerability was not found to be related to demographic parameters, Mini Mental Status Examination score, or type of dementia. High temperature and low air humidity during the first month of treatment were found to be associated with a higher incidence of skin reactions and secondary treatment disruption.
Transdermal rivastigmine induced a higher incidence of cutaneous adverse events than previously reported in a prospective clinical trial. Moreover, it seems that meteorological conditions favoring skin perspiration (high temperature and low air humidity) during the first month of treatment might have an influence on transdermal rivastigmine skin tolerability.
本回顾性研究旨在评估我们记忆诊所患者中因皮肤不良反应而停用透皮利伐斯的发生率。此外，我们还测试了气候条件是否可能对导致治疗中断的皮肤刺激有影响。
我们对 2008 年 6 月至 2010 年 12 月期间在布鲁格曼大学医院记忆诊所开始使用透皮利伐斯的患者进行了回顾性分析。比利时皇家气象研究所提供了当地的气象数据。
共有 26.9%的患者在利伐斯的应用部位出现不良反应，导致 19.2%的患者停止治疗。皮肤耐受性与人口统计学参数、简易精神状态检查评分或痴呆类型无关。治疗的第一个月高温和低空气湿度与皮肤反应和继发性治疗中断的发生率较高有关。
与前瞻性临床试验相比，透皮利伐斯引起的皮肤不良事件发生率更高。此外，似乎有利于皮肤出汗的气象条件（高温和低空气湿度）在治疗的第一个月可能对透皮利伐斯的皮肤耐受性有影响。
